美爆发罕见细菌感染 44人患病18人死亡

  • 感染病例,天然细菌,死亡
  • 中国新闻网


中新社休斯敦3月4日电 11个县报告44例感染病例,美国威斯康辛州数月来爆发致命细菌感染,截至目前共导致18人死亡。

据美国广播公司4日报道,卫生官员称,该州罕见的感染缘于一种天然细菌Elizabethkingia anopheles,可在土壤、淡水和水库中发现。威斯康辛州包括哥伦比亚县在内的11个县,报告有44例感染,患者症状包括发烧、呼吸急促、发冷或皮肤发红。

细菌感染的爆发主要影响65岁以上老人,每一位感染者以往都至少有一种严重疾病。

“确定威斯康辛州细菌对患者的影响,是一个复杂过程。”州卫生官员麦基翁(Karen McKeown)本周发表声明表示,从2015年11月1日至2016年3月2日,该州共收到44个病例报告,18名丧生者的血液中均发现细菌感染。比照医学文献中以往疫情记载表明,今次很可能创下这种细菌有史以来规模最大的爆发纪录。

州和联邦卫生官员说,调查人员目前正在测试包括水在内的环境样本,寻找细菌爆发的源头。

田纳西州范德堡大学医学中心传染病专家沙夫纳(William Schaffner)表示,“感染这种细菌是非常罕见的,其更有可能发生在医疗设备或器械被细菌污染的卫生保健机构内。”

他指出,这种细菌不会在人与人之间传播,但对早产儿尤其致命,因为他们的免疫系统没有发育完全。

美国疾病控制与预防中心(CDC)表示,通常每年每个州平均有5至10例该种细菌感染病例,这次的爆发最为严重,CDC目前派遣了5名调查人员到当地,未来还将增派人手协助威州阻止感染进一步爆发。


This link:http://www.chemcd.com/news/25176.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.